Science 37
Uses advanced telemedicine technology and patient-centric innovative networked clinical research models to rapidly accelerate biomedical discovery and bring down the costs of clinical trials.
Launch date
Employees
Market cap
€31.5m
Enterprise valuation
(€19m) (Public information from Mar 2024)
Share price
$5.75 SNCE
Morrisville North Carolina (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Revenues | 23.7m | 59.6m | 70.1m | 58.4m | 62.8m | 75.2m |
% growth | - | 151 % | 18 % | (17 %) | 8 % | 20 % |
EBITDA | (26.5m) | (24.6m) | (139m) | (32.4m) | (17.1m) | (2.9m) |
% EBITDA margin | (112 %) | (41 %) | (199 %) | (55 %) | (27 %) | (4 %) |
Profit | (31.7m) | (94.3m) | (51.0m) | (72.8m) | (38.4m) | (24.9m) |
% profit margin | (134 %) | (158 %) | (73 %) | (125 %) | (61 %) | (33 %) |
EV / revenue | - | 20.4x | -0.8x | -0.3x | 0.3x | 0.6x |
EV / EBITDA | - | -49.4x | 0.4x | 0.5x | -1.1x | -15.8x |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$6.5m | Series A | ||
$31.0m | Series B | ||
$29.0m | Series C | ||
$31.0m | Series B | ||
$35.0m | Series D | ||
$40.0m | Late VC | ||
$75.0m Valuation: $1.1b 44.3x EV/LTM Revenues -39.7x EV/LTM EBITDA | SPAC IPO | ||
$200m Valuation: $1.1b 44.3x EV/LTM Revenues -39.7x EV/LTM EBITDA | SPAC Private Placement | ||
* | $38.0m Valuation: $38.0m | Acquisition | |
Total Funding | €339m |
Recent News about Science 37
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Science 37
EditACQUISITION by Science 37 Feb 2023